TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Children's Healthy Living Program for Remote Underserved Minority Populations in the Pacific Region
Brief Summary: The goal is to build social/cultural, political/economic, and physical/built environments that will promote active play and intake of healthy food to prevent young child obesity in the Pacific Region. Our methods will support local culture in order to achieve this goal in these remote, underserved native populations. CHL will engage the community, and focus on capacity building and sustainable environmental change.

The focus of the CHL community-based program is to promote healthy eating and to increase physical activity. In order to demonstrate effectiveness, the investigators will recruit and measure children in six communities selected in each of our jurisdictions in the Pacific. These represent intervention communities, comparison communities, and temporal communities.


Options:
A: Arm Label: CHL program; Type: EXPERIMENTAL; Interventions: Other: CHL program | Arm Label: Delayed Optimized CHL program; Type: OTHER; Interventions: Other: Delayed Optimized CHL program | Arm Label: Temporal; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: CHL program; Assigned to Arm(s): CHL program | Intervention Type: OTHER; Name: Delayed Optimized CHL program; Assigned to Arm(s): Delayed Optimized CHL program
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Intervention group
C: Intervention Type: BEHAVIORAL; Name: Physical activity and diet; Assigned to Arm(s): N/A
D: Arm Label: Nutrition and Physical Activity; Type: EXPERIMENTAL; Interventions: Behavioral: The Food Friends | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The Food Friends; Assigned to Arm(s): Nutrition and Physical Activity

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Study Comparing the Safety and Efficacy of the InnFocus MicroShunt® Glaucoma Drainage System to Standard Trabeculectomy In Subjects With Primary Open Angle Glaucoma
Brief Summary: Assess the safety and effectiveness of the InnFocus MicroShunt when used to lower intraocular pressure (IOP) in subjects with primary open angle glaucoma where the IOP is not controlled when using maximum tolerated glaucoma medications.


Options:
A: Arm Label: Hydrus Aqueous Implant (Treatment); Type: EXPERIMENTAL; Interventions: Device: Hydrus Aqueous Implant | Arm Label: Cataract Surgery (Control); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cataract surgery | Intervention Type: DEVICE; Name: Hydrus Aqueous Implant; Assigned to Arm(s): Hydrus Aqueous Implant (Treatment) | Intervention Type: PROCEDURE; Name: Cataract surgery; Assigned to Arm(s): Cataract Surgery (Control)
B: Arm Label: Trabectome-IOL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabectome-IOL | Arm Label: Trab-IOL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trab-IOL | Intervention Type: PROCEDURE; Name: Trabectome-IOL; Assigned to Arm(s): Trabectome-IOL | Intervention Type: PROCEDURE; Name: Trab-IOL; Assigned to Arm(s): Trab-IOL
C: Arm Label: InnFocus MicroShunt; Type: EXPERIMENTAL; Interventions: Device: InnFocus MicroShunt | Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Glaucoma Surgery | Intervention Type: PROCEDURE; Name: Glaucoma Surgery; Assigned to Arm(s): Trabeculectomy | Intervention Type: DEVICE; Name: InnFocus MicroShunt; Assigned to Arm(s): InnFocus MicroShunt
D: Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabeculectomy with mitomycin C | Arm Label: Implant; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Baerveldt implant | Intervention Type: PROCEDURE; Name: Baerveldt implant; Assigned to Arm(s): Implant | Intervention Type: PROCEDURE; Name: Trabeculectomy with mitomycin C; Assigned to Arm(s): Trabeculectomy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Study Comparing the Safety and Efficacy of the InnFocus MicroShunt® Glaucoma Drainage System to Standard Trabeculectomy In Subjects With Primary Open Angle Glaucoma
Brief Summary: Assess the safety and effectiveness of the InnFocus MicroShunt when used to lower intraocular pressure (IOP) in subjects with primary open angle glaucoma where the IOP is not controlled when using maximum tolerated glaucoma medications.


Options:
A: Arm Label: Trabectome-IOL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabectome-IOL | Arm Label: Trab-IOL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trab-IOL | Intervention Type: PROCEDURE; Name: Trabectome-IOL; Assigned to Arm(s): Trabectome-IOL | Intervention Type: PROCEDURE; Name: Trab-IOL; Assigned to Arm(s): Trab-IOL
B: Arm Label: InnFocus MicroShunt; Type: EXPERIMENTAL; Interventions: Device: InnFocus MicroShunt | Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Glaucoma Surgery | Intervention Type: PROCEDURE; Name: Glaucoma Surgery; Assigned to Arm(s): Trabeculectomy | Intervention Type: DEVICE; Name: InnFocus MicroShunt; Assigned to Arm(s): InnFocus MicroShunt
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: phacoemulsification alone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: iStent Trabecular Micro-Bypass Stent | Intervention Type: PROCEDURE; Name: phacoemulsification alone; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: iStent Trabecular Micro-Bypass Stent; Assigned to Arm(s): 2
D: Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabeculectomy with mitomycin C | Arm Label: Implant; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Baerveldt implant | Intervention Type: PROCEDURE; Name: Baerveldt implant; Assigned to Arm(s): Implant | Intervention Type: PROCEDURE; Name: Trabeculectomy with mitomycin C; Assigned to Arm(s): Trabeculectomy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Study Comparing the Safety and Efficacy of the InnFocus MicroShunt® Glaucoma Drainage System to Standard Trabeculectomy In Subjects With Primary Open Angle Glaucoma
Brief Summary: Assess the safety and effectiveness of the InnFocus MicroShunt when used to lower intraocular pressure (IOP) in subjects with primary open angle glaucoma where the IOP is not controlled when using maximum tolerated glaucoma medications.


Options:
A: Arm Label: CyPass Micro-Stent + Cataract Surgery; Type: EXPERIMENTAL; Interventions: Procedure: Cataract Surgery, Device: CyPass Micro-Stent | Arm Label: Cataract Surgery Only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cataract Surgery | Intervention Type: PROCEDURE; Name: Cataract Surgery; Assigned to Arm(s): Cataract Surgery Only, CyPass Micro-Stent + Cataract Surgery | Intervention Type: DEVICE; Name: CyPass Micro-Stent; Assigned to Arm(s): CyPass Micro-Stent + Cataract Surgery
B: Arm Label: Trabectome-IOL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabectome-IOL | Arm Label: Trab-IOL; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trab-IOL | Intervention Type: PROCEDURE; Name: Trabectome-IOL; Assigned to Arm(s): Trabectome-IOL | Intervention Type: PROCEDURE; Name: Trab-IOL; Assigned to Arm(s): Trab-IOL
C: Arm Label: InnFocus MicroShunt; Type: EXPERIMENTAL; Interventions: Device: InnFocus MicroShunt | Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Glaucoma Surgery | Intervention Type: PROCEDURE; Name: Glaucoma Surgery; Assigned to Arm(s): Trabeculectomy | Intervention Type: DEVICE; Name: InnFocus MicroShunt; Assigned to Arm(s): InnFocus MicroShunt
D: Arm Label: Trabeculectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trabeculectomy with mitomycin C | Arm Label: Implant; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Baerveldt implant | Intervention Type: PROCEDURE; Name: Baerveldt implant; Assigned to Arm(s): Implant | Intervention Type: PROCEDURE; Name: Trabeculectomy with mitomycin C; Assigned to Arm(s): Trabeculectomy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Topical Tranexamic Acid Versus Intravenous Administration to Reduce Blood Transfusion Rate in Total Knee Arthroplasty Surgery: Phase III, Unicentric, Controlled,Double Blind, Randomized Non Inferiority Clinical Trial.
Brief Summary: The main objective is to evaluate the efficacy and safety of topical Tranexamic Acid (TA) to reduce the blood transfusion rate in total knee arthroplasty. The secondary endpoints are to estimate the visible blood loss at 24 hours after surgery, and invisible blood loss through serial counting of Hb/Htc. Methodology. TRANEX1 is a phase III, unicentric, controlled, randomized, double blind clinical trial that compare efficacy and safety of topical TA versus intravenous TA in a multimodal protocol, with no-inferiority criteria(n=79).


Options:
A: Arm Label: Evicel; Type: EXPERIMENTAL; Interventions: Drug: Evicel | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Evicel; Assigned to Arm(s): Evicel
B: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Experimental | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Comparator
C: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline (0.9% NaCl) | Arm Label: Topical; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid, Drug: Normal saline (0.9% NaCl) | Arm Label: Systemic; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid, Drug: Normal saline (0.9% NaCl) | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Systemic, Topical | Intervention Type: DRUG; Name: Normal saline (0.9% NaCl); Assigned to Arm(s): Control, Systemic, Topical
D: Arm Label: Topical tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Topical tranexamic acid, Drug: Enoxaparin | Arm Label: Floseal®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Floseal®, Drug: Enoxaparin | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Topical tranexamic acid; Assigned to Arm(s): Topical tranexamic acid | Intervention Type: DRUG; Name: Floseal®; Assigned to Arm(s): Floseal® | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Control group, Floseal®, Topical tranexamic acid

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pivotal Response Group Treatment for Parents of Young Children With Autism
Brief Summary: This is a research study examining the effectiveness of pivotal response treatment group (PRTG) in targeting language skills in young children with autism. Research has demonstrated that behavioral interventions, such as Pivotal Response Training (PRT), lead to improvements in the core symptoms of autism. The purpose of this study is to further examine the effectiveness of teaching pivotal response treatment to parents of children with autism in a group format. To determine the effectiveness of pivotal response training group (PRTG) it will be compared to another parent education group by conducting a randomized controlled 12-week trial.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Early intervention blending several tx approaches, w/ focus | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early intervention blending several treatment approaches | Intervention Type: BEHAVIORAL; Name: Early intervention blending several tx approaches, w/ focus; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Early intervention blending several treatment approaches; Assigned to Arm(s): 2
B: Arm Label: Caregiver Education Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Caregiver-Education Intervention | Arm Label: Caregiver-Mediated Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Caregiver-Mediated Intervention | Intervention Type: BEHAVIORAL; Name: Caregiver-Mediated Intervention; Assigned to Arm(s): Caregiver-Mediated Intervention | Intervention Type: BEHAVIORAL; Name: Caregiver-Education Intervention; Assigned to Arm(s): Caregiver Education Intervention
C: Arm Label: Pivotal Response Training (PRT); Type: EXPERIMENTAL; Interventions: Behavioral: Pivotal Response Training (PRT) | Arm Label: Parent Education Group (PEG); Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Parent Education Group (PEG) | Intervention Type: BEHAVIORAL; Name: Pivotal Response Training (PRT); Assigned to Arm(s): Pivotal Response Training (PRT) | Intervention Type: BEHAVIORAL; Name: Parent Education Group (PEG); Assigned to Arm(s): Parent Education Group (PEG)
D: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes
Brief Summary: The objective of the proposed research is to evaluate the efficacy and safety of the use of metformin in addition to standard insulin therapy in overweight and obese children and adolescents, age 12-\<20 years, with type 1 diabetes for at least 1 year. Secondary objectives are to assess the effect of metformin on C-peptide levels, a measure of how much insulin is still being produced by the beta cells of the pancreas, and on vascular dysfunction. In addition, an ancillary study is planned to assess if metformin will improve tissue-specific insulin resistance in type 1 diabetes using a hyperinsulinemic euglycemic clamp.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Orlistat; Type: EXPERIMENTAL; Interventions: Drug: Orlistat | Intervention Type: DRUG; Name: Orlistat; Assigned to Arm(s): Orlistat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: N/A
C: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin (glucophage) | Arm Label: Oral Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: oral placebo | Intervention Type: DRUG; Name: Metformin (glucophage); Assigned to Arm(s): Metformin | Intervention Type: OTHER; Name: oral placebo; Assigned to Arm(s): Oral Placebo
D: Arm Label: Litramine; Type: EXPERIMENTAL; Interventions: Device: Litramine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Placebo | Intervention Type: DEVICE; Name: Litramine; Assigned to Arm(s): Litramine | Intervention Type: DEVICE; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: "EXHALE" A Randomized Clinical Trial Comparing the Effects of a 12 Week Supervised Exercise Intervention Versus Usual Care for Advanced Stage Lung Cancer Patients.
Brief Summary: The aim of this study is to evaluate the effect of twelve weeks of a physical and psycho-social program consisting of: supervised, structured exercise training in a group of advanced lung cancer patients (cardio and strength training, relaxation training) twice weekly. Primary outcome is (VO2peak). The hypotheses are that patients who undergo this intervention will increase maximal oxygen uptake (VO2peak), strength (1RM), functional capacity (6MWD) and quality of life (HRQOL) and reduce the level of anxiety and depression compared to those who do not.


Options:
A: Arm Label: Exercise Intervention Program (EIP); Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention, Other: Care-Management-Phone-Calls | Arm Label: Care-Management-Phone-Calls (CMPC); Type: ACTIVE_COMPARATOR; Interventions: Other: Care-Management-Phone-Calls | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Exercise Intervention Program (EIP) | Intervention Type: OTHER; Name: Care-Management-Phone-Calls; Assigned to Arm(s): Care-Management-Phone-Calls (CMPC), Exercise Intervention Program (EIP)
B: Arm Label: Inspiratory muscle training; Type: EXPERIMENTAL; Interventions: Other: Inspiratory muscle training, Other: Placebo comparator: standard physiotherapy | Arm Label: Standard physiotherapy; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo comparator: standard physiotherapy | Intervention Type: OTHER; Name: Inspiratory muscle training; Assigned to Arm(s): Inspiratory muscle training | Intervention Type: OTHER; Name: Placebo comparator: standard physiotherapy; Assigned to Arm(s): Inspiratory muscle training, Standard physiotherapy
C: Arm Label: Resistance training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Resistance training
D: Arm Label: Control - usual care; Type: OTHER; Interventions: Other: Usual care | Arm Label: Exercise + usual care; Type: OTHER; Interventions: Other: Usual care, Other: Exercise | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Control - usual care, Exercise + usual care | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise + usual care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Mediated by the Src Homology-2-domain-containing Inositol 5' Phosphatase [SHIP1] Pathway
Brief Summary: The primary objective of this study is to evaluate the effect of 6 weeks of treatment with once daily administration of AQX-1125 compared to placebo on average daily pain in subjects with interstitial cystitis/bladder pain syndrome (IC/BPS), during and after treatment, using a standardized 11-point numerical rating scale (NRS) pain score recorded by electronic diary


Options:
A: Arm Label: Group A: Liposome encapsulated BoNT-A; Type: EXPERIMENTAL; Interventions: Drug: Liposome encapsulated BoNT-A | Arm Label: Group B: BoNT-A 200 U in Normal saline; Type: EXPERIMENTAL; Interventions: Drug: BOTOX 200U in normal saline | Arm Label: Group C: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Liposome encapsulated BoNT-A; Assigned to Arm(s): Group A: Liposome encapsulated BoNT-A | Intervention Type: DRUG; Name: BOTOX 200U in normal saline; Assigned to Arm(s): Group B: BoNT-A 200 U in Normal saline | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Group C: Normal saline
B: Arm Label: AQX-1125; Type: EXPERIMENTAL; Interventions: Drug: AQX-1125 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AQX-1125; Assigned to Arm(s): AQX-1125 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Post Tibial Nerve Stimulation Group (PTNS); Type: EXPERIMENTAL; Interventions: Device: NURO TM | Arm Label: Sham Group; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Intervention Type: DEVICE; Name: NURO TM; Assigned to Arm(s): Post Tibial Nerve Stimulation Group (PTNS) | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham Group
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: PF-04383119 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: PF-04383119; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of Endometrial Biopsy on the Outcome of In Vitro Fertilization (IVF) /Intra-Cytoplasmic Sperm Injection (ICSI) Treatment (Endoscratch): A Feasibility Pilot Study
Brief Summary: This study aims to see if taking a small sample from the lining of the womb (the 'scratch') before starting in vitro fertilization (IVF) treatment can influence the chance of getting pregnant and having a healthy, term baby.

This study also aims to explore why an embryo is not accepted or indeed rejected by the lining of the womb. This will be analysed by carefully looking at the sample taken from the lining of the womb under the microscope and analysing the levels of natural killer (NK) cells. These cells are thought to regulate the implantation process and to be altered in some women with infertility and miscarriage.


Options:
A: Arm Label: Endometrial biopsy arm; Type: EXPERIMENTAL; Interventions: Procedure: Endometrial biopsy, Device: Transvaginal ultrasound | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Endometrial biopsy; Assigned to Arm(s): Endometrial biopsy arm | Intervention Type: DEVICE; Name: Transvaginal ultrasound; Assigned to Arm(s): Endometrial biopsy arm
B: Arm Label: Endometrial injury group; Type: EXPERIMENTAL; Interventions: Procedure: Endometrial injury | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Procedure: Control group | Intervention Type: PROCEDURE; Name: Endometrial injury; Assigned to Arm(s): Endometrial injury group | Intervention Type: PROCEDURE; Name: Control group; Assigned to Arm(s): Control group
C: Arm Label: Scrathcing; Type: EXPERIMENTAL; Interventions: Procedure: scratching | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Procedure: scratching | Intervention Type: PROCEDURE; Name: scratching; Assigned to Arm(s): Control, Scrathcing
D: Arm Label: Office hysteroscopy and endometrial snip; Type: EXPERIMENTAL; Interventions: Procedure: Office hysteroscopy and endometrial snip | Arm Label: Office hyteroscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Office hysteroscopy | Intervention Type: PROCEDURE; Name: Office hysteroscopy and endometrial snip; Assigned to Arm(s): Office hysteroscopy and endometrial snip | Intervention Type: PROCEDURE; Name: Office hysteroscopy; Assigned to Arm(s): Office hyteroscopy

Answer: A